FDA doesn't approve most generics reviewed in first cycle

Share this article:
An HHS Office of Inspector General report says the FDA does not approve 96% of new generic drugs reviewed during their first cycle because they contain chemistry deficiencies. The document, which examines generic drug reviews for 2006, says the agency exceeded the 180-day review requirement for 46% of original applications. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions